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ABSTRACT 
 
Normal cell homeostasis in a tissue requires a delicate balance between cell growth, 
maintenance and death, tightly controlled by an intricate interplay between proto-oncogenes 
and tumor suppressor genes. When the balance is tipped due to genetic or epigenetic lesions 
in such genes, diseases such as cancer may arise.  
MYC transcription factors has been known to regulate up to 15% of mammalian genes 
involved in diverse intracellular programs, including cell cycle regulation, cell growth, 
differentiation, apoptosis, and senescence, and is deregulated in many human cancers. MYC 
recruits different co-factors for activation or repression of transcription, such as MAX or Miz-
1, respectively. MYC is tightly regulated at multiple levels, including transcription, post-
translational modification and turnover. Ubiquitylation is one such control, and although 
ubiquitylation is mainly associated with proteasomal degradation, it has also been shown to 
be involved in non-proteolytic functions such as DNA replication and repair. 
Tumorigenesis is a multistep process that involves activating or inactivating mutations or 
epigenetic changes in more than one gene to confer growth advantages to the cell. MYC is 
known to cooperate with another oncoprotein, RAS, to transform rodent cells. While RAS 
has been found to suppress MYC-induced apoptosis, MYC also inhibits RAS-induced 
senescence, thereby blocking two main anti-tumorigenic mechanisms in the cell and may, at 
least in part, explain the basis for the MYC/RAS cooperativity. 
Inactivation of MYC in mouse tumor models demonstrated tumor regression with well-
tolerated side effects, suggesting that MYC is a potential and suitable target for anti-cancer 
therapy. However, pharmacological targeting of transcription factors is considered difficult 
and no anti-MYC drugs are clinically available today. 
In this thesis, we deepen our understanding on MYC biology by studying different proteins 
that cooperate and interact with MYC (Paper I to III), and identify small molecules that 
would target specific interactions involving MYC (Paper IV).  
In Paper I, we found that oncogenic MYC and RAS do not cooperate to cancel out each 
other’s intrinsic anti-tumorigenic barrier, namely apoptosis and senescence, in normal human 
fibroblasts as they do in murine fibroblasts, even in the absence of the tumor suppressor p53. 
This is in contrast to previous results from human melanocytes, where MYC was reported to 
suppress BRAF- and partially NRAS-induced senescence, thus suggesting that these anti-
tumor barriers are orchestrated differently in different species and in different cell types.  
In Papers II and III, we discovered new regulatory mechanisms for MYC. In Paper II, we 
found that the cyclin-dependent kinase (CDK) inhibitor p27KIP1 (p27) binds MYC and targets 
it for degradation. p27 is upregulated by interferon-ɣ (IFN-ɣ) and by other growth inhibitory 
signals. We also found that IFN-ɣ treatment leads to the degradation of MYC, mediated by 
upregulation of p27. There is significant clinical relevance between high activity of nuclear 
p27 levels and low MYC expression in tumor samples, and this correlates with a good 
prognosis and a positive clinical outcome. This may provide insights into strategies to target 
MYC-driven tumors, for example by finding ways to upregulate p27 expression and activity, 
utilizing IFN-ɣ in treatment modalities, stimulating immune cells to produce IFN-ɣ by 
immunotherapy and finding methods to combine these strategies to combat MYC-driven 
tumors.  
In Paper III, we uncovered a novel F-box protein, FBXO28, that ubiquitylates MYC in a non-
proteolytic manner, and enhances MYC transcriptional activity and downstream pathways. 
Phosphorylation of SCFFBXO28 by CDK1/2 during the cell cycle is required for its efficient 
ubiquitylation of MYC. Depletion of FBXO28 or expression of its dominant negative F-box 
mutant, negates this function and results in reduction of MYC-driven transcription, 
transformation and tumorigenesis. High MYC expression coupled with high FBXO28 
expression and phosphorylation are strong and independent predictors of poor prognosis in 
human breast cancer. Our data suggests that the CDK-FBXO28-MYC axis is a potential 
molecular drug target in MYC-driven cancers, including breast cancer.  
In Paper IV, we conducted a small molecule screen and found, MYCMI-6, that binds MYC, 
inhibits MYC/MYCN:MAX interactions, and impeded tumor cell growth in a MYC-
dependent manner in a variety of tumor cell cultures and in a mouse tumor model of MYCN-
amplified neuroblastoma. Importantly, this compound is highly specific and potent, has a 
good therapeutic window and does not have severe side effects. This discovery provides 
proof of principle of protein-protein targeting. MYCMI-6 can be used as a molecular tool to 
study MYC:MAX interactions and is a good candidate for drug development. 
Altogether, the projects involved in this thesis provide insights into molecular pathways 
involved in MYC oncogenic activity, regulation, and transcription functions, shed light in 
MYC-RAS cooperativity, identified new proteins interacting with MYC and small molecules 
interfering with MYC function. This is of importance not only to increase the basic 
knowledge on mechanisms through which MYC contributes to tumor development, but will 
hopefully also contribute to the development of new therapeutic strategies to combat MYC-
driven cancer in the future. 
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1 INTRODUCTION 
 
1.1 CANCER 
 
In 2018, cancer cases around the world have risen to 18.1 million, leading to 9.6 million 
deaths (Organization, 2018). Cancer is the term used in the scientific literature to refer to a 
progressive and malignant tumor, which is an agglomeration of uncontrollably dividing cells, 
that can grow and spread (metastasize) beyond their boundaries to other organs (Greaves and 
Maley, 2012; Hanahan and Weinberg, 2011). It is not a single disease but rather a systemic 
disease. There are currently 10 hallmarks and common underlying characteristics identified 
that are shared in different combinations across the different cancers, making this complex 
disease more understandable through science (Figure 1) (Hanahan and Weinberg, 2011). Of 
these, sustained proliferative signaling, resistance to cell death, enabling replicative 
immortality, evasion of growth suppressors and genomic instability and mutation will be 
expounded upon later in the introduction and will be connected to the work in this thesis. 
 
Figure 1: The eight hallmarks and two enabling characteristics (Genome instability and mutation, 
and tumor-promoting inflammation) of cancer (adapted from Hanahan and Weinberg (2011)) in 
compliance with the conditions of Elsevier user licence. Copyright © 2011 Elsevier, Inc. 
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Cancer can be caused by genetic or environmental factors, the former leading to cancers at a 
young age (Apostolou and Fostira, 2013; Sorrell et al., 2013), while the latter leads to cancer 
later in life and is estimated to be the cause of 90-95% of all cancers (Anand et al., 2008). 
Environmental factors can be chemical, physical or biological in nature. Numerous types of 
cancers have been caused by both natural and synthetic compounds (Poon et al., 2014; 
Wogan et al., 2004), X-ray and UV light (Borek, 1993), as well as viral infections, for 
example with human papillomavirus (HPV) (White et al., 2014). 
Conventional therapeutic strategies against cancer include chemotherapy, radiotherapy and 
surgery. While these therapies may benefit some patients, they also have disadvantages. 
Chemotherapy is not specific, and can target both tumor and healthy cells, leading to side 
effects such as hair loss and anemia (Caley and Jones, 2012). Further, chemotherapeutic 
drugs can introduce mutations to healthy as well as tumor cells. This is more serious and can 
lead to the development of new, resistant or more aggressive tumors (Caley and Jones, 2012; 
Vogelstein and Kinzler, 1993). Radiotherapy, while mostly targeted to a specific site, may 
also similarly lead to secondary tumors (Drooger et al., 2015). Surgery may avoid these 
unwanted effects but is limited to tumors that are located at non-vital organs, such as breast 
and prostate, and may have unacceptable cosmetic outcomes (Bertozzi et al., 2017).  
Novel approaches, such as immunotherapy and targeted therapies, have been developed more 
recently. In immunotherapy, antibodies, cytokines, transfer of cancer-specific immune cells 
and cancer vaccines, among other strategies, are used to activate the immune system to kill 
tumor cells (Saied et al., 2014; Srivastava and McDermott, 2014; Vanneman and Dranoff, 
2012). Targeted therapy, on the other hand, uses small molecules to directly hit a specific 
protein or group of proteins that contribute to the tumor formation, thereby causing the tumor 
cells to die or stop growing (Widmer et al., 2014). These novel approaches show promise of 
being more personalized. Different therapies can also be combined to achieve a more 
effective treatment (Saied et al., 2014; Vanneman and Dranoff, 2012). However, the 
development of drug resistance, and hence relapse, is still a concern, despite discoveries of 
new therapies (Fong and Park, 2009; Holohan et al., 2013). Thus it is important to identify 
the drivers of tumor growth and optimize treatments. 
 
1.2 ONCOGENES AND TUMOR SUPPRESSOR GENES 
 
Tumorigenesis, i.e. the development of tumors, is a multistep process, involving at least two 
mutations in rodent cells and four to seven mutations in human cells (Hahn et al., 1999; 
Hanahan and Weinberg, 2000; Land et al., 1983; Renan, 1993). Mutations occur randomly 
but when hitting so called “driver genes”, which confer growth advantages to the target cell, 
they are selected for by a process similar to that of Darwinian evolution (Foulds, 1954; 
Nowell, 1976). 
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There are two main classes of genes that, when mutated or deregulated, would give a growth 
advantage that contribute to the development of tumors: proto-oncogenes and tumor 
suppressor genes. Both classes of genes exist as part of the normal cell genome and usually 
play important roles in normal cell physiology (Vogelstein and Kinzler, 2004).  
Gain-of-function mutations in proto-oncogenes, resulting in their over-activation, or 
overexpression result in the formation of tumor-promoting so called oncogenes (Vogelstein 
and Kinzler, 2004). Examples of proto-oncogenes are MYC and RAS.  
MYC family of proto-oncogenes, c-MYC, MYCN and MYCL, code for transcription factors 
that control the expression of many genes involved in distinct processes relevant for 
tumorigenesis, including cell growth, apoptosis, metabolism, immortalization, differentiation 
and stem cell function (Meyer and Penn, 2008). Deregulation of MYC expression (Pelengaris 
et al., 2002b) or perturbations in MYC’s degradation (Bahram et al., 2000; Isobe et al., 2009; 
Yeh et al., 2004) have been linked to the development of many types of human tumors. As 
the projects in this thesis are all related to MYC, a chapter will be dedicated to discuss more 
on this proto-oncogene. 
RAS family of proto-oncogenes, HRAS, KRAS and NRAS, encode for membrane-bound 
GTPases that transduces extracellular signals from growth factor receptors to activate 
downsteam effectors (Serrano et al., 1997). It is one of the central regulators of growth factor-
induced cell proliferation and survival in normal and cancer cells. Human cancers often 
contain amplifications of or activating point mutations in RAS (Pratilas and Solit, 2010). RAS 
will be discussed further in later chapters. 
Tumor development also requires inactivating or loss-of-function mutations of tumor 
suppressor genes, such as genes encoding for p53 and retinoblastoma protein (pRB), which 
are the main brakes in the cell cycle, and control cell survival and genome integrity 
(Vogelstein and Kinzler, 2004).  
The p53 protein is a transcription factor that functions in cell growth inhibitory pathways and 
is able to promote cell death, senescence or cell cycle arrest under conditions which exert 
cellular stress. Point mutations disrupting its DNA-binding capacity or increase in factors that 
binds and inactivate its function, like MDM2, are among the common ways to disrupt the p53 
pathway (Oren, 2003; Prives and Hall, 1999; Vogelstein et al., 2000) 
pRB is also a transcription factor and it is one of the proteins that directly control the 
transition from G1 to S phase of the cell cycle, and its activation causes cells to undergo 
arrest in the G1 phase. The RB gene can be inactivated by mutation and the pRB protein is an 
important target of DNA tumor viruses (Classon and Harlow, 2002). 
A delicate balance between cell growth, maintenance and death, tightly controlled by an 
intricate interplay between proto-oncogenes and tumor suppressor genes, governs normal cell 
homeostasis. Genetic or epigenetic lesions in these genes tip the balance, hence leading to the 
development of tumors. 
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1.3 CELL CYCLE  
 
The cell cycle is a precise and regulated process through which cells duplicate and segregate 
their genome and organelles to produce daughter cells and proliferate. The eukaryotic cell 
cycle is divided into four discrete phases: gap1 (G1), DNA synthesis (S), gap2 (G2) and 
mitosis (M). Cells that are resting and non-proliferating exit the cell cycle and enter a 
quiescence state (G0). Cell cycle durations differ between different organisms and even 
between different cell types in an organism. In human, cell cycle of the somatic cells takes 
about 24 hours to complete. The G1, S and G2 phases together make up the cell cycle 
interphase and typically take between 18-22 hours, with the G1 phase being the most variable 
and often the longest. The M phase takes only one hour and is the shortest phase.  
G1 is the phase where the cells monitor if the environmental factors are favorable for 
replication before it decides to proceed with the cell cycle or go into G0. In the presence of 
mitogenic signals and favorable conditions, it will pass a checkpoint, called the restriction 
point (R point), and proceed into the S phase where the DNA is replicated. After replication 
of the genome is completed, the cells go into G2 phase, which is a phase where the cell 
prepares for M phase. G2 contains an important checkpoint to ensure that the DNA is 
correctly duplicated and structurally intact before entering into the M phase. This last phase, 
mitosis, is where the cell divides into two daughter cells, and the process is divided into four 
sub-phases: prophase (condensation of the DNA), metaphase (alignment of duplicated 
chromosomes), anaphase (separation of chromosomes) and telophase (decondensation of the 
DNA). There is another checkpoint mid-mitosis to ensure that chromosomes are properly 
attached to the mitotic spindle before separating. Extracellular signals are able to affect the 
process only in the early G1 phase. After the cell cycle passes the R point, it will proceed 
autonomously according to schedule until the end point, mitosis (reviewed in Nurse (2011)). 
Cell cycle progression is regulated by cyclins, cyclin-dependent kinases (CDKs) and CDK 
inhibitors (CKI). Cyclins bind and activate CDKs, which are serine/threonine kinases that 
phosphorylate substrates of relevance for cell cycle progression. There are four families of 
cyclins, namely Cyclin A, B, D and E, and four CDKs, namely CDK1, 2, 4 and 6, that have 
direct participation in the mammalian cell cycle, although there are more members of the 
family. In general, the levels of S and M phase CDKs are rather constant but their activities 
depend on the availability and levels of cyclins, which fluctuates in a tightly regulated 
manner, in synchronization with the progression through the different phases of the cell cycle. 
The cell cycle is kept in check by CKIs, which negatively regulate the process by inhibiting 
the CDKs. Inhibitors of CDK4/6 (INK4) comprise of  p16INK4A (p16), p15INK4B (p15), 
p18INK4C (p18) and p19INK4D (p19), while the CIP/KIP family p21CIP1 (p21), p27KIP1 (p27) and 
p57KIP2 (p57) inhibit CDK2 and CDK1 complexes (Weinberg, 2014). These CKIs are also 
involved in other cellular processes besides cell cycle progression and will be brought up 
later in this thesis. 
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In the G1 phase of the cell cycle, growth factor signaling upregulates the levels of cyclin D1, 
D2 and D3. Cyclin D associates with and activates CDK4 or CDK6, which phosphorylates 
pRB. pRB is a cell cycle brake that controls the R point by interacting with and sequestering 
the transcription factor E2F. At the G1/S border, increased expression of cyclin E, which 
binds and activates CDK2, occurs. Upon hyper-phosphorylation of pRB, which involves 
cyclin D/CDK4/6 and cyclin E/CDK2, E2F is released and will upregulate the expression of 
several proteins required for DNA replication and metabolism (Trimarchi and Lees, 2002). 
On top of this, Cyclin D/CDK4/6 sequesters p27, which inhibits CDK2, and in doing so, 
further increases cyclin E/CDK2 activity and promotes the G1 progression (Polyak et al., 
1994; Reynisdottir et al., 1995). Cyclin E/CDK2, drives the G1 to S phase transition by 
targeting pRB and inducing degradation of p27 via the E3 ligase SKP2 (Elledge and Harper, 
1998; Sheaff et al., 1997; Vlach et al., 1997). Cyclin A, which is one of the proteins induced 
by E2F, starts to pair with CDK2 in the early S phase, where cyclin E is degraded via a 
CDK2-dependant pathway (Welcker et al., 2004). Cyclin A/CDK2 participates in the 
initiation of DNA replication. During the late S phase and into the G2 phase, cyclin A binds 
CDK1, but as the cell cycle proceeds from the G2 to M phase, CDK1 will form complexes 
with cyclin B, and this complex trigger M-phase entry. After mitosis, the level of cyclin 
B/CDK1 drops and the cell waits for a signal to start another cell cycle (Arellano and 
Moreno, 1997) (reviewed in Hydbring et al. (2016)). 
 
 
Figure 2: The mammalian cell cycle. The illustration depicts the cell cycle phases, the cyclin/cyclin-
dependent kinase (CDK) complexes (black) and growth/tumor-inhibitors (orange) involved, and their 
periods of activity during the cell cycle. MYC’s (blue) points of intervention in the cell cycle are also 
depicted (picture from Hydbring et al. (2017), open access). 
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1.4 SENESCENCE AND APOPTOSIS 
 
Cancers do not arise from a single gene defect. In a normal mammalian cell, the activation of 
a single oncogene triggers intrinsic safeguard mechanisms via tumor suppressor genes, which 
limit its tumorigenic potential and protect the cell. Thus, each mutated or deregulated cancer-
critical genes would only be a contributing factor, and it is only when several genes are 
defective does an invasive cancer develop (Vogelstein and Kinzler, 2004). 
Apoptosis is a “programmed” cell death that dictates the controlled destruction of cellular 
constituents and their ultimate engulfment by other cells. Generally, there are several 
pathways through which apoptosis occur, all leading to the activation of a group of cysteine 
proteases called “caspases” and a complex cascade of events that ends with the final demise 
of the cell. Activated initiator caspases 2, 8, 9 and 10 starts the caspase cascade which acts on 
downstream effector caspases 3, 6, 7 and 14. In the extrinsic pathway, cell surface receptors 
such as FAS induce the apoptosis signal, leading to the activation of caspases 8, after which 
caspase 3 and 7 get activated, leading to apoptosis. The intrinsic pathway is induced by 
cellular stress or via crosstalk with the extrinsic pathway and is controlled by the pro-
apoptotic factors of the BCL-2 family such as BAX, BAK and BID, which target 
mitochondrial membrane and induces cytosolic cytochrome c release. The anti-apoptotic 
family members of the BCL-2, namely BCL-2 and BCL-XL, balances the apoptotic pathway. 
The apoptosis program is normally a homeostatic mechanism to maintain cell populations, 
and occurs during development and aging. It may also be employed as a defense mechanism 
when cells are damaged or in immune reactions (reviewed in Elmore (2007)).  
Senescence is a state of irreversible growth arrest and normally occurs in normal cells as a 
result of telomere erosion through the aging process. The difference between a senescent and 
a quiescent cell is that the former remains metabolically active in the senescent state while the 
latter lies dormant in the G0 phase of the cell cycle. Some senescence cells have been shown 
to be able to secrete factors, including cytokines and chemokines, which can induce responses 
such as inflammation. The secretome is profoundly different from that of a normal cell and is 
called the senescence-associated secretory phenotype (SASP). Senescence can be induced 
prematurely by acute stress signals such as deregulation of oncogenes, which results in 
replicative stress and generation of reactive oxygen species (ROS), and is termed Oncogene-
Induced Senescence (OIS). This often triggers a DNA damage response and is associated 
with increased levels of the tumor suppressor p53, which activates downstream effectors, 
such as the expression of the CKI p21. The p16/pRB pathway has also been shown to be 
important in senescence induction in several cell types (reviewed in Kuilman et al. (2010)). 
As outlined above, p16 in an inhibitor of CDK4/6, and thus prevents the cyclin D/CDK4/6 
complex from hyperphosphorylating pRB. Thus pRB remains bound to the E2F transcription 
factor and inhibits the transcription of the other factors involved in the cell cycle progression, 
hence bringing the cell cycle to a halt (Dublin et al., 1998; Li et al., 2011; Muirhead et al., 
2006; Parry et al., 1995). 
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Both apoptosis and premature senescence can be employed as extreme responses to cellular 
stress and are important tumor-suppressive mechanisms, by quickly eliminating, or 
preventing the growth of damaged or stressed cells, respectively. 
 
1.5 CELLULAR SIGNALING 
 
Cells receive signals from their surrounding environment that dictate the cell fate; if they 
should proliferate, differentiate, die, or go through some other process. These signals can 
come in the form of growth factors, growth inhibitory factors, cytokines and hormones, 
amongst others. Ligands from extracellular space bind and activate their cognate cell surface 
receptors. The receptors in turn transduce the information through the plasma membrane into 
the cytoplasmic intracellular environment to induce signaling cascades that eventually reach 
the cell nucleus to regulate gene expression (Shaw and Cantley, 2006). There are multiple 
signaling pathways and among the major ones are receptor tyrosine kinases (RTK), Wnt, 
Hedgehog (Hh), Notch, nuclear receptors, mTOR, TGF-β, NFkB and JAK/STAT pathways. 
Although the signaling pathways have distinct intermediate players, and there is extensive 
crosstalk between them. The basic mechanism of some signaling pathways that are often 
deregulated in cancer and are of relevance to this thesis will be briefly outlined below.  
 
1.5.1 The RAS, MAPK and PI3K signaling pathways 
 
Receptor tyrosine kinases (RTKs) are similarly structured receptors that transmit signals from 
growth factors. Binding of the ligand leads to dimerization and activation of the receptors, 
which transphosphorylate each other on tyrosine residues. Through the function of adaptor 
proteins such as Grb2, which recognize phospho-tyrosine through its SH2 domain, inactive 
GDP-bound RAS is recruited and converted to its active GTP-bound form and remains 
activated until the GTP is hydrolyzed to GDP. GTP-bound RAS activates the RAF protein 
kinase family, triggering the Mitogen-Activated Protein Kinase (MAPK) pathway. RAF 
phosphorylates and activates MEK, which in turn phosphorylates and activates Extracellular 
signal Regulated Kinase (ERK1/2) protein kinases. ERK functions in activating factors 
involved in protein synthesis in the cytoplasm, and regulating transcription by 
phosphorylating several transcription factors in the nucleus that stimulate cell proliferation 
and growth (Downward, 2003; Finocchiaro et al., 2008; Katz et al., 2007).  
RAS can also activate the Phosphatidyl Inositol-3 Kinase (PI3K) pathway. This pathway is 
also activated for example by Insulin-like Growth Factor (IGF)-1/IGF1-receptor (IGFR) 
RTK, which is involved in cell growth and survival. PI3K is a lipid kinase that 
phosphorylates 2 phosphatidylinositol 4,5-biphosphate (PIP2) to generate PIP3, which is then 
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recognized by and activates the AKT/PKB kinase. Activated AKT signaling inhibits 
apoptosis and promotes cell growth and survival by phosphorylating a number of substrates, 
including caspase 9, Bad, MDM2 (Cantley, 2002; Engelman et al., 2006), and suppressing 
proteins that negatively regulate MYC-mediated cell proliferation such as GSK-3β (Frame 
and Cohen, 2001) and FOXO proteins (Bouchard et al., 2004). PI3K also activates the mTOR 
pathway leading to increased translation. The components of the MAPK and the PI3K 
signaling pathways can interact and crosstalk with each other to promote the growth and 
survival of transformed cells.  
Single activating mutations on RAS are prevalent in some types of human cancers such as 
pancreatic, colon and lung cancers where the frequency of RAS mutations are being as high as 
91%, 42% and 33%, respectively. When this happens, the mutated RAS proteins produced 
become constitutively active and are no longer require upstream signaling for activity. Such 
deregulation in the signaling pathways contributes to one hit on the way to transformation, by 
allowing the cell to acquire self-sufficiency to growth signals, one of the hallmarks of cancer 
(Hanahan and Weinberg, 2011; Vogelstein and Kinzler, 2004).  
 
1.5.2 The Interferon-ɣ and JAK/STAT Pathway 
 
One family of cytokines relevant to this thesis is the Interferons (IFN), which are involved in 
regulating cell growth, antiviral defense and immune response. It comprises of three classes, 
namely IFN-α, −β and-γ, and are further subdivided into two types, type I and II, based on 
their structure, function and stimuli that induce their expression. Type I consists of IFN-α and 
-β, while type II consist only of IFN-γ. IFN-γ has been found to be secreted by several 
components of the immune system, including T helper type 1 (Th1) lymphocytes and natural 
killer (NK) cells, B cells, natural killer T cells and professional antigen-presenting cells 
(APCs) (Stark et al., 1998). This type II interferon plays a role in many biological functions, 
such as in anti-proliferative and anti-viral pathways, activation of macrophages and 
regulation of cell differentiation and apoptosis (Boehm et al., 1997; Hu et al., 2002). IFN-γ 
possesses anti-tumor properties and has in fact been used in some cancer treatment (Gleave et 
al., 1998). 
There are two ways of regulating IFN-γ activity, either by controlling production of IFN- γ or 
modulating the IFN-γ signaling. IFN-γ production is controlled by interleukin 12 (IL-12,) and 
18 (IL-18) in natural killer cells, and by T-cells receptor engagement in T-helper cells. IFN-ɣ 
binds and activates the receptor tyrosine kinases Janus kinases (JAKs), which then 
phosphorylate transcription factors in the cytoplasm called signal transducer and activator of 
transcription (STATs). Upon phosphorylation, STATs translocate into the nucleus, bind 
specific DNA sites and direct the transcription of IFN target genes. There are four known 
mammalian JAKs (JAK1, JAK2, JAK3 and Tyk2) and seven STATs (STAT1, 2, 3, 4, 5a, 5b 
and 6) (Aaronson and Horvath, 2002; Decker and Kovarik, 2000; Stark et al., 1998).  
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STAT1 has shown to be necessary for the anti-proliferative effects of IFNs. For example, 
expression of the CDK inhibitor p21, which is a negative regulator of the cell cycle, is 
upregulated by IFN-γ. On the other hand, the expression of positive cell cycle regulators, like 
MYC, cyclin D3 and CDC25a, is reduced in response to IFN-α (Chin et al., 1996; Kominsky 
et al., 1998; Ramana et al., 2000; Tiefenbrun et al., 1996). In this thesis, we showed that IFN-
γ also mediates MYC degradation (Bahram et al., 2016) (Paper II). 
Other than the JAK/STAT pathway, IFN-γ receptors can also mediate biological responses 
through the RAS/RAF (MAPK) and PI3K pathways (Kalvakolanu, 2003; Stark et al., 1998). 
 
1.6 GENE EXPRESSION AND REGULATION 
 
Most signaling through different pathways is transmitted to the nucleus where it regulates 
gene expression. Many of the targets of mutation or deregulation in cancer are transcription 
factors, such as MYC, p53 and pRB, as have been outlined above. Gene expression can be 
regulated at multiple steps and involves numerous components. In this chapter, only certain 
aspects of the process will be briefly discussed, all in relation to this thesis work. 
 
1.6.1 Chromatin Structure and DNA Accessibility 
 
Genetic information is stored in the DNA, which is nearly 2 meters long for a human cell and 
is tightly packed in a highly organized structure of chromosomes to fit in the cell nucleus. 
The strand of DNA is wrapped around an octamer core consisting of histone H2A, H2B, H3 
and H4 proteins, forming the basic unit of chromatin, the nucleosome, which is then further 
organized to form the chromatin structure. The chromatin structure is highly dynamic and can 
be modulated to make it accessible for proteins involved in transcription, replication and 
DNA repair (Woodcock and Ghosh, 2010). The histone-DNA contact interface can be altered 
by covalent histone modification and chromatin-remodeling complexes, thus regulating gene 
expression (Peterson and Laniel, 2004; Wang et al., 2007a, b). 
Histone modifying enzymes, called writers and erasers, are recruited by transcription 
regulators to covalently add or remove groups of histones marks at histone tails, respectively. 
These groups include acetyl (ac) and methyl (me) of lysine (K) and arginine (R), phospho, 
ubiquitin, SUMO and ribosyl groups. Different combinations of the histone marks code for 
different biological outcomes. Examples of active or repressed histone marks are given below 
(Nicholson et al., 2015; Peterson and Laniel, 2004).  
 Active chromatin/ transcription: H3K4me3, H3K27ac, H3K9ac, H3K79me2 
 Repressed chromatin/ transcription: H3K9me2/3, H3K27me2/3, H4K20me3 
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Histone acetyl transferases (HATs) and histone de-acetyl transferases (HDACs) are examples 
of writers and erasers, for the addition (acetylation) or removal (deacetylation) of acetyl 
groups at histones tails, respectively (Allfrey et al., 1964; Nicholson et al., 2015). GCN5 was 
already known to be a transcriptional co-activator when it was discovered as the first HAT 
(Brownell et al., 1996), thus it became clear that histone modifications can regulate 
transcription directly. Later, other transcriptional co-activators like CBP/p300 were shown to 
have HAT activities while transcriptional co-repressors like SIN3-RPD3 were linked to 
HDAC activities (reviewed in Peterson and Laniel (2004)). 
The different histone modifications can change the charge of the histone tail, and can thereby 
affect the affinity between DNA and nucleosomes, but they also constitute a “histone code” 
controlling the binding of specific non-histone proteins to chromatin. These histone codes can 
be recognized by another group of proteins, called readers, which bind chromatin 
modifications and decipher the chromatin state of the locus. For instance, bromodomain-
containing proteins are readers that bind acetylated histones, while methylated histones 
recruit chromodomain-containing proteins (Nicholson et al., 2015; Yun et al., 2011).  
Histone modifications, chromatin remodeling complexes and other recruited non-histone 
proteins form part of the “epigenetic landscape” , which regulates chromatin structure, and in 
turn affects gene expression in a reversible and highly dynamic manner, without changing the 
DNA sequence ((Jakopovic et al., 2013; Wolffe and Hayes, 1999) reviewed in Peterson and 
Laniel (2004)). DNA methylation is another factor affecting the epigenetic landscape. 
Hypomethylation of promoter DNA is an active mark, which leads to transcriptional 
activation, while hypermethylation is a repressive mark that leads to transcriptional 
repression, in part due to methyl-CpG-binding proteins bound at the methylated DNA, and 
the recruitment of HDACs and chromatin remodeling factors, all leading to a repressive 
transcription mark and repressed chromatin (Ballestar and Wolffe, 2001; Zwart et al., 2001). 
 
1.6.2 Transcription and Transcription Factors  
 
Information encoded in the DNA molecules is transcribed into RNA molecules, after which 
protein-encoding mRNAs are translated into functional proteins (Cramer et al., 2008). The 
transcription is driven by RNA polymerases, comprising of RNA polymerase I, II and III (Pol 
I, II and III), which synthesizes rRNA, mRNA and tRNA, respectively. Protein-encoding 
genes are only transcribed by Pol II, which also transcribes non-coding RNAs like miRNAs.  
Transcriptional regulation occurs mostly during transcription initiation. There are various 
control regions positioned on a protein-encoding gene, namely the core promoter, the 
proximal and distal promoters, enhancers and silencers (Delgado and León, 2006). 
The initiation of Pol II-mediated transcription requires the recruitment of general 
transcription factors (GTFs), such as TFIIB, TFIID, TFIIA, TFIIE, TFIIF and TFIIH, which 
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forms the pre-initiation complex (PIC) and directs the polymerase to the transcription start 
site (TSS). The PIC containing RNA pol II recognizes promoters containing a TA-rich DNA 
sequence called TATA box. TFIID is able to recognize TATA boxes through its subunits 
TATA-binding protein (TBP) and TBP-associated factors (TAFs). Another important 
element called initiator (Inr) sequence is also located within the transcription start site 
(Kornberg, 2007; Moqtaderi et al., 1996).  
DNA-binding transcription factors bind to specific promoter or enhancer DNA sequences in 
target genes that are upstream of the transcription initiation site. When bound to enhancer 
elements, the transcription factor is able to bring a specific promoter to the PIC by looping 
the DNA (Delgado and León, 2006). These two components are then connected by a 
multiprotein complex called the Mediator (Kornberg, 2005; Malik et al., 2005). RNA Pol II 
then leaves the PIC and start synthesizing RNA. Binding of the transcription factor to 
silencers, though, would result in repression of the gene expression (reviewed in Delgado and 
León (2006)). 
Transcription machinery in higher eukaryotes would pause after the initiation steps and 
transcribing few nucleotides. This is known as promoter-proximal pausing and is an 
important mechanism of transcription regulation. In RNA pol II-driven transcription, pausing 
is mediated by DRB sensitivity-inducing factor (DSIF) and negative elongation factor 
(NELF) (Nechaev and Adelman, 2011). CyclinH/CDK7 which are subunits of TFHII 
contributes to clearance of the promoter by phosphorylating the Ser5 residue of the C-
terminal domain (CTD) of RBP1, the largest subunit of RNA polymerase II, thus allowing 
pause release and transcription elongation to proceed (Espinosa, 2010; Hengartner et al., 
1998). Ser 5 phosphorylation by TFIIH also contributes to the recruitment of capping enzyme 
to the 5’ end of nascent mRNA. 
Processive transcription elongation is mediated by positive transcriptional elongation factor b 
(P-TEFb) complex, consisting of CDK9 and cyclin T. It phosphorylates Ser2 of the CTD tail 
and elongation factors DSIF and NELF, leading to the dissociation of DSIF and NELF from 
RNA pol II. Ser-2 phosphorylation also promotes recruitment of the mRNA splicing complex 
3’ as well as processing and termination factors (Ahn et al., 2004; Meinhart and Cramer, 
2004). 
 
1.7 THE UBIQUITIN PROTEASOME SYSTEM 
 
The ubiquitin-proteasome system was discovered as a regulated protein degradation 
mechanism involved in a wide range of cellular processes including the transcription, protein 
quality control, signal transduction, cell cycle, apoptosis, receptor mediated endocytosis and 
metabolic pathways (Ciechanover, 2005). Quite a portion of the human genome is found to 
 20 
be devoted to the ubiquitin pathway, taking into account both proteolytic and non-proteolytic 
functions (Semple et al., 2003).  
The ubiquitin-proteasome system involves two steps. The first step is ubiquitylation, where 
ubiquitin, a 76-amino acid polypeptide (Goldstein, 1974; Goldstein, 1975; Schlesinger et al., 
1975), is attached to the substrate. This is followed by degradation of the ubiquitylated 
substrate by the 26S-proteasome. Ubiquitylation proceeds through three enzymatic steps 
involving at least three types of enzymes. Firstly, ubiquitin is activated by E1, a ubiquitin 
activating enzyme, which forms a thiol-ester bond with the C-terminal glycine on the 
ubiquitin protein an ATP-dependent process. Secondly, ubiquitin is transferred to E2, a 
ubiquitin conjugating enzyme that accepts ubiquitin from the E1 by a transesterification 
reaction. Finally, the ubiquitin is conjugated to its substrate either directly by the E2 or 
through E3 ubiquitin-ligases. E3-ligases are enzymes that can catalyze the conjugation 
process, which results in covalent attachment of ubiquitin to a specific substrate (for reviews 
see (Ardley and Robinson, 2005; Fang and Weissman, 2004; Pickart and Eddins, 2004; 
Weissman, 2001). Upon attachment of one ubiquitin molecule to the target protein, more 
ubiquitins can be attached to a lysine residue on the surface of the first ubiquitin molecule to 
build a poly-ubiquitin chain, or the target protein can remain mono-ubiquitylated (Kim et al., 
2007). Recent studies have indicated that the polyubiquitin chain may already be formed on 
the E2 and E3 enzymes before conjugation to the substrate (Ben-Saadon et al., 2006; Li et al., 
2007). 
There are seven internal lysine residues (K6, K11, K27, K29, K33, K48 and K63) on 
ubiquitin, all of which have been found to participate in ubiquitin-ubiquitin interactions. 
There are several different formations of the polyubiquitin chains. Similar lysine residues can 
be used for conjugating the ubiquitin molecule, creating a homotypic chain, or different 
lysines can be used to form a mixed-linkage chain. Other ubiquitin-like molecules such as 
SUMO can also be conjugated, thus forming a heterologous polyubiquitin chain (for review 
see (Ikeda and Dikic, 2008)). The length of the ubiquitin chain and specific lysine residues 
involved will determine the substrate fate and function, whether to be targeted for 
degradation or other non-proteolytic functions like DNA-repair (Spence et al., 1995), 
transcriptional activation (Adhikary et al., 2005a) or many other processes. 
 
The E3 ubiquitin ligases  
Ubiquitin-E3-ligases are classified into four classes based on their structure motifs: RING 
(Really Interesting New Gene) finger, HECT (Homologous to E6-AP Carboxyl Terminus), 
U-box E3 and PHD (Plant Homeo-Domain)-finger E3 ligases (Deshaies and Joazeiro, 2009; 
Hatakeyama et al., 2001; Rotin and Kumar, 2009; Scheffner and Kumar, 2014). For the 
purpose of this thesis, the RING finger will be briefly discussed on.  
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One of the extensively studied subclass of the RING-finger E3 ligase family is the SCF 
(Skp1-Cullin1-F-box protein) E3 ligase. The SCF complex consists of the Cul1, Rbx1, Skp1, 
and F-box protein subunits. The Cul1 and Rbx1 subunits form a catalytic core that recruits 
the upstream E2 enzyme while the variable F-box subunit mediates interaction with Skp1 and 
also confers substrate specificity to the whole complex (Deshaies, 1999; Jackson and 
Eldridge, 2002; Zheng et al., 2002).  
There are about seventy F-box proteins that have been identified in human genome. They are 
categorized based on their interaction domain, namely F-box proteins containing WD40 
repeats (FBXW), leucin-rich repeats (FBXL) or other domain (FBXO) (Skaar and Pagano, 
2009). 
Some SCF E3 ligases have been shown to play important role during the cell cycle, such as 
the S-phase associated kinase associated protein 2 (SKP2/FBXL1) and FBW7 (FBXW7)  that 
will be mentioned in later chapters in this thesis. We have also discovered a novel E3 ligase, 
FBXO28, which activates transcription via MYC. This will be discussed more in the paper III 
results and discussion. 
 
1.8 MYC 
 
1.8.1 Master Regulator 
 
MYC is the human homologue of the avian myelocytomatosis retroviral oncogene, v-myc, 
first described more than 30 years ago (Hayward et al., 1981; Sheiness and Bishop, 1979; 
Vennstrom et al., 1982). The MYC family of proto-oncogenes comprises of 3 members, MYC 
(c-MYC), MYCN and MYCL, which encode nuclear oncoproteins/transcription factors of the 
basic helix-loop-helix-leucine zipper (bHLHZip) family. MYC has been estimated to regulate 
up to 15% of all genes in humans and coordinate the expression of genes involved in diverse 
intracellular programs, including, but not limited to, cell cycle, proliferation and growth, 
energy metabolism, DNA replication, global RNA production and many biosynthetic 
pathways, as well as differentiation, apoptosis and senescence  (Adhikary and Eilers, 2005; 
Dang et al., 2006; Eilers and Eisenman, 2008; Kress et al., 2015; Larsson and Henriksson, 
2010; Meyer and Penn, 2008). MYC proteins also play important roles in normal 
development and cell physiology. In mice studies, loss of c- and N-MYC had been found to 
be embryonic lethal (Baudino et al., 2002; Charron et al., 1992; Davis et al., 1993; Knoepfler 
et al., 2002; Stanton and Parada, 1992; Stanton et al., 1992), but L-MYC knockout do not 
seem to lead to any phenotypic abnormalities (Pirity et al., 2006).  
MYC controls expression of its target genes for the many different functions by recruiting 
different co-factors for activation or repression of transcription. For its transcriptional and 
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oncogenic activity, MYC must dimerize with MAX, another bHLHZip protein that is 
ubiquitously expressed. The MYC:MAX complex binds to DNA recognition elements at 
target gene promoters, primarily E-box sequence CACGTG or its variants, and activates 
transcription.  MYC represses transcription at alternative DNA sites through association with 
other cofactors such as the transcription factor Miz-1 (Adhikary and Eilers, 2005; Eilers and 
Eisenman, 2008; Meyer and Penn, 2008). MYC also recruits a number of other cofactors, 
such as histone acetyl transferases (HATs), histone methyl transferases (HMTs), ATP-
dependent chromatin remodeling complexes, E3 ubiquitin ligases and kinases, amongst 
others, to up- or downregulate its target genes and execute the different cellular processes 
(Adhikary et al., 2005b; Hydbring et al., 2017; Kress et al., 2015). 
In 2012, studies emerged to propose MYC as a global amplifier of transcription. MYC is 
proposed to interact with all active promoters and enhancers and, upon its upregulation, MYC 
would invade them and amplify the active transcriptional program further. This model 
provides an explanation for why high MYC levels often increase the total RNA content in 
cells (Lin et al., 2012; Nie et al., 2012). This view was opposed by others who stand by the 
idea that MYC regulates specific sets of genes, be it for coding genes, miRNA regulation or 
long non-coding RNAs (lncRNAs), which, however, in turn regulates global gene expression 
(Kress et al., 2015; Sabo et al., 2014). 
Given its central role in transcription and regulation of many cellular processes, it comes as 
no surprise that the MYC family possesses potent oncogenic capabilities and contributes to a 
large number and variety of human tumors (See section: MYC in Cancer). Thus MYC 
expression is tightly regulated and is usually kept at low levels, only to be induced by specific 
cues such as growth factor signaling (Marcu et al., 1992; Wierstra and Alves, 2008). 
 
1.8.2 MYC Structure, Expression and Regulation 
 
The MYC gene is found in all major metazoan lineages and possibly as far back as unicellular 
progenitors (Kress et al., 2015; Young et al., 2011), but is absent in the nematode C. elegans 
(Young et al., 2011). The MYC family of genes consists of three exons. Exon 1 is the target 
site for transcription factors and is noncoding, while exons 2 and 3 contain the coding 
regions. Two promoters at the 5’ end of exon 1 accounts for 90-95% of transcription of MYC 
mRNAs, which are about 2.2 and 2.4 kb, from which MYC proteins of about 64 and 67 kDa 
are translated (DePinho et al., 1987; Katoh et al., 1988; Sawai et al., 1990; Watson et al., 
1983). 
MYC, MYCN and MYCL1 proteins are highly conserved in most of the regions termed the 
MYC homology boxes (MB). The N-terminus of MYC contains MBI (amino acids (aa) 44–
63) and MBII (aa 128–143), which form part of the transactivation domain (TAD; aa 1–143). 
In the central region lies MBIIIa (aa 188–199), which is conserved in MYC and MYCN but 
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not in MYCL, MBIIIb (aa 259–270), and MBIV (aa 304–324), the latter containing the 
nuclear localization signal (NLS; aa 320–328). The C-terminus of MYC contains the basic 
region (b; aa 355–369) and the helix–loop–helix–leucine zipper (HLH–LZ; aa 370–439). The 
bHLHZIP component is required for MYC binding to its transcription partner protein, MAX, 
and for full transformation of primary and immortal cells. The basic region confers the 
specificity of binding to canonical and non-canonical E-boxes DNA sequences (Figure 3) 
(reviewed in Meyer and Penn (2008)). 
MYC is regulated at multiple levels, including transcription, translation, post-translational 
modification and turnover.  
The MYC proto-oncogene is a direct target and effector downstream of growth-regulatory and 
oncogenic signaling pathways, such as, but not limited to, RTKs, Notch, WNT, Hedgehog 
and Janus kinase (JAK)–signal transducer and activator of transcription 3 (STAT3) signaling, 
which induce MYC transcription. On the other hand, MYC transcription is repressed by 
transforming growth factor‑β (TGFβ) signaling (reviewed in (Kress et al., 2015; Wierstra and 
Alves, 2008)). Many of these signaling pathways act on proximal promoter elements and 
distal enhancers, including super-enhancers, regulating transcription of the MYC loci 
(reviewed in Dang (2012) and Hydbring et al. (2017)). 
MYC translation can be affected by a number of signaling cascades, such as mTOR signaling 
including mTOR complex 1 (mTORC1)–S6K1, eIF4A and eIF4F, MAPK–HNRPK and 
MAPK–FOXO3A signaling cascades (reviewed in (Hydbring et al., 2017; Kress et al., 
2015)). 
Post-translationally, MYC activity and/or turnover are regulated via a number of 
modifications, such as phosphorylation, acetylation, glycosylation, proteolytic or non-
proteolytic ubiquitylation, and small ubiquitin-related modifier (SUMO)-ylation (Kamemura 
et al., 2002; Vervoorts et al., 2003)(reviewed in Hydbring et al. (2017)). Of interest to this 
thesis is the phosphorylation and ubiquitylation of MYC and will be expanded on later in this 
chapter.  
The MYC protein is very short-lived, with a half-life of about 15–30 min, depending on cell 
type (Gregory and Hann, 2000; Gregory et al., 2003). PI3K and RAS signaling pathways 
have been found to cooperate to increase MYC stability (Sears et al., 1999; Sears et al., 
2000). MYC is then regulated and degraded mainly by the ubiquitin/proteasome system.  
Several E3 ubiquitin ligases have been shown to ubiquitylate MYC with different 
consequences for MYC´s function and stability, including SCFFBXW7, SCFSKP2, 
HUWE1/HECTH9, SCFTRCP, TRUSS, PIRH2, CHIP, SCFFBXL14, SCFFBXO28 and SCFFBX29 
(reviewed in Hydbring et al. (2017)). SCFSKP2, for example, has been shown both to induce 
degradation of MYC and to work as a transcriptional cofactor (von der Lehr et al., 2003). 
FBXW7 is a classical E3 ligase for MYC degradation (Welcker et al., 2004; Yada et al., 
2004; Yeh et al., 2004). 
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Studies on MYC transformation and regulation of its stability and activity has very much 
been focused on the MYC phosphorylation sites Thr58 and Ser62 in the MBI region, which 
has been associated with degradation of MYC by via the E3 ligase FBXW7 (Bahram et al., 
2000; Hann, 2006; Henriksson et al., 1993; Pulverer et al., 1994). A variety of proliferative 
stimuli, for example cytokines, mitogenic signals, UV exposure and DNA damage, activates 
specific kinases to phosphorylate MYC at Ser62 (reviewed in Hann (2006)). Phosphorylation 
at Ser62 stabilizes and activates MYC, and also serves as a platform for Thr58 
phosphorylation by glycogen synthase kinase 3β (GSK3β) (Sears et al., 2000), which in turn 
recruits phosphatase PP2A to dephosphorylate Ser62 and then the E3 ligase FBXW7 to 
degrade MYC (Welcker et al., 2004; Yada et al., 2004; Yeh et al., 2004). 
Our contribution from this thesis work has been the discovery of a novel E3 ligase, 
SCFFBXO28, which non-proteolytically ubiquitylates MYC in a cell cycle dependent manner 
and activates MYC activity of relevance to tumorigenesis (paper III). We have also found a 
new pathway for MYC degradation mediated by IFN-ɣ and p27 pathway (paper II), with the 
involvement of an unknown E3 ligase. These will be further discussed in the results and 
discussion section. 
 
 
Figure 3: MYC structure and interaction partners. Upper part: MYC protein structure with MBI-IV, 
the conserved MYC homology boxes I–IV; Thr-58 and Ser-62, regulatory phosphorylation sites; TAD, 
transcriptional activation domain; NLS, nuclear localization signal; bHLHZip, basic region/helix–
loop–helix/leucine zipper. Lower part: Interacting and regulatory proteins that are of interest for this 
thesis interacting with respective regions. 
 
Negative feedback loops also keep MYC level in check. MYC has been found to represses its 
own promoter in a concentration-dependent manner as a form of homeostatic control 
mechanism (reviewed in Meyer and Penn (2008)). In this complex regulatory mechanism 
MYC target genes loops to control the transcription. For example, PTEN tumor suppressor 
that is activated by MYC, enhances PRC2 activity, which in turn represses many genes, 
including MYC itself (Kaur and Cole, 2012). In another scenario, MYC expression is 
positively regulated by E2F1. MYC, in turn, induces expression of microRNAs miR-17 and 
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miR-20, which downregulate E2F1 transcription factors, hence autorepressing MYC 
expression (O'Donnell et al., 2005). 
Intrinsic anti-proliferative programs are also elicited to counter MYC activity. MYC 
activation under conditions of limited survival factors induces apoptosis by both p53-
dependent and -independent mechanisms (reviewed in Green and Evan (2002); Nilsson and 
Cleveland (2003)). In the absence of CDK2, activation of MYC induces senescence 
(Campaner et al., 2010). The induction of these two phenomena by MYC will be further 
explained in later chapters. 
 
1.8.3 MYC and Cell Cycle 
 
MYC plays an important role in cell cycle progression. In quiescent G0 cells, MYC 
expression is very low. Upon increase in mitogenic signaling, MYC expression is rapidly 
induced and drives the transition from G0 to G1 to from G1 to S phase. It has been shown 
that quiescent cells re-enter the cell cycle and proceed through G1 and S phase upon 
expression of MYC alone, even in the absence of serum factors. Also, it was found that G1 
phase in the cell cycle is often shortened in cells with activated MYC (Bouchard et al., 2004) 
(reviewed in Meyer and Penn (2008)).  
MYC has been shown to directly or indirectly activate most of the cell cycle players, 
including cyclin D/CDK4, cyclin E/CDK2, cyclin A/CDK2, cyclin B/CDK1, E2F1, E2F2, 
and cell division cycle 25A (CDC25A) ((Amati et al., 1998; Bouchard et al., 1999; Coller et 
al., 2000; Galaktionov et al., 1996; Hermeking et al., 2000; Leone et al., 1997; Luscher, 2001; 
Mateyak et al., 1999), also reviewed in Meyer and Penn (2008) and Pelengaris et al. (2002a)). 
These factors are important both for the G1-S phase transition, to drive the cell cycle through 
the R point, and also for G2-M phase transition. Additionally, MYC directly or indirectly 
downregulates or inhibits several cell cycle checkpoint genes, such as CKIs, like p15INK4B, 
p21CIP1, p27KIP1 and GADD45 and GADD153 (Chandramohan et al., 2008; Obaya et al., 
1999; Oster et al., 2002; Seoane et al., 2002; Staller et al., 2001; Wu et al., 2003). 
The complexity of the cell cycle regulation increases with regulatory loops to provide a tight 
control over cell proliferation. One example is that MYC also upregulates miR-17-5p and 
miR-20a, which downregulates E2F translation (O'Donnell et al., 2005). Another example is 
our finding that p27 targets MYC for degradation, as will be discussed in paper II.  
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1.8.4 MYC and Apoptosis 
 
In order to maintain homeostasis, activation or ectopic expression of MYC will induce the 
cell to undergo apoptosis under the conditions where survival factors are limiting. This 
sensitizes cells to stimuli such as death receptor signaling (Fas/TNF-α), DNA damage and 
cancer drugs (reviewed in Nilsson and Cleveland (2003)). MYC-induced apoptosis is 
mediated through two known pathways: p53 upregulation via p19ARF, and cytochrome 
release via BAX activation and/or repression of BCL-XL and BCL-2 (Zindy et al., 1998). 
In tumorigenesis, oncogenic events will hinder the pro-apoptotic function of MYC by 
inducing anti-apoptotic factors, like BCL-2, BCL-XL or BIM, or repressing/ablating pro-
apoptotic factors such as p53 and p19ARF ((Eischen et al., 1999), reviewed in (Meyer and 
Penn, 2008)). It was found that MYC-induced apoptosis is dependent on the level and 
intensity of MYC expression. Low level of activated MYC would lead to proliferation and is 
better at initiating tumorigenesis, while high level of MYC overexpression would lead to 
apoptosis. However, in the presence of anti-apoptotic factors, MYC apoptotic function is 
inhibited and MYC overexpression leads to tumorigenesis (Evan et al., 1992; Murphy et al., 
2008). Consequently, apoptosis can be induced in MYC-driven tumors by reviving the 
abrogated pathways, leading to destruction of the tumor cells (Goga et al., 2007; Meyer et al., 
2006). 
 
1.8.5 MYC and Senescence 
 
Senescence is another anti-proliferative program elicited by MYC overexpression. High 
levels of MYC lead to replication stress and genomic instability. This can lead to premature 
cellular senescence that is independent of the telomere, a condition termed oncogene-induced 
senescence (OIS). Studies have showed that overexpressed MYC can provoke OIS when the 
anti-senescence and DNA repair gene, WRN, is ablated (Grandori et al., 2003). 
Another study showed that CDK2 knockout mouse embryonic fibroblasts would initially 
enter a proliferative state when exposed to MYC activation and then undergo senescence, 
without induction of replicative stress as in the WRN model. This was accompanied by 
upregulation of p21Cip1 and p16INK4a, and thus dependent on the ARF–p53–p21Cip1 and 
p16INK4a–pRb pathways. Moreover, in the Eµ-myc transgenic mouse lymphoma model, 
CDK2 ablation sensitizes cell to MYC-induced senescence, with delayed onset of lymphoma 
(Campaner et al., 2010). 
Paradoxically, MYC plays a dual role with regards to senescence and has been shown to 
suppress senescence induced by other oncogenes. Our group and others have shown that 
MYC suppresses activated RAS/BRAF-induced (BRAF is a downstream effector of RAS) 
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senescence in rat embryonic fibroblast (REF) cells and in a BRAFV600E/MYC mouse lung 
tumor model. Reciprocally, MYC inactivation in this system restores BRAFV600E– and 
NRASQ61R–induced senescence (Hydbring et al., 2010; Juan et al., 2014; Tabor et al., 2014). 
Phosphorylation of MYC at Ser62 has been shown to be required for this suppressive 
function. It was also shown that cyclin E/CDK2 phosphorylates this site, and that the CDK-
inhibitor p27Kip1 and CDK2-selective pharmacological compounds inhibit phosphorylation 
and abrogates this function of MYC (Hydbring et al., 2010). Further, as mentioned above, 
MYC also promotes senescence in the absence of CDK2 (Campaner et al., 2010). Thus in 
this scenario, CDK2 acts as a switch between MYC function in repressing or inducing 
senescence (reviewed in Hydbring et al. (2017)).  
Human melanoma cells expressing mutant BRAFV600E or NRASQ61R has also been shown to 
undergo p16INK4A- or p53-independent senescence upon depletion of MYC. Conversely, 
overexpression of MYC suppresses BRAFV600E– and NRASQ61R–induced senescence in 
melanocytes, albeit more efficiently with the former. This suggests that in melanoma with 
BRAFV600E or NRASQ61R mutations, MYC overexpression functions to sustain tumorigenesis 
by suppressing the innate senescence program that would have otherwise been elicited 
(Zhuang et al., 2008) (see also chapter MYC in Cancer -Oncogene Cooperation).  
 
1.8.6 MYC in Cancer 
 
Despite being subjected to stringent regulation in the cell at many levels, MYC deregulation 
has been found in a wide variety of human malignancies, tallying to more than half of all 
human tumors (Nilsson and Cleveland, 2003; Vita and Henriksson, 2006). The central role of 
MYC in growth control and orchestrating a large variety of genes and pathways, endows 
MYC with strong oncogenic potential. This allows MYC activation to contribute directly to 
and being a driver of malignant transformation (Adams et al., 1985; Gabay et al., 2014; Land 
et al., 1983; Leder et al., 1986; Meyer and Penn, 2008), often correlating strongly with tumor 
progression to advanced stages and poor prognosis (Adhikary and Eilers, 2005; Eilers and 
Eisenman, 2008; Larsson and Henriksson, 2010; Meyer and Penn, 2008; Nilsson and 
Cleveland, 2003). Apart from driving tumor initiation and progression, MYC is also needed 
to maintain the transformed state, even in tumors driven by other oncogenes (Felsher and 
Bishop, 1999; Gabay et al., 2014; Jain et al., 2002; Pelengaris et al., 2002b; Sodir et al., 2011; 
Soucek et al., 2008; Zhuang et al., 2008). 
Among the mechanisms leading to MYC overexpression discovered early in the history of 
MYC research includes insertional mutagenesis, chromosomal translocation and gene 
amplification. Insertional mutagenesis is where a non-mutated cellular gene is activated by 
the insertion of a foreign promoter or enhancer, in this case from a retrovirus. In 
chromosomal translocation, MYC oncogene is juxtaposed to the immunoglobin (Ig) heavy 
chain loci by consistent recombination, which often gives rise to lymphomas (reviewed in 
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Meyer and Penn (2008)). Amplifications of MYC (Alitalo et al., 1983; Dalla-Favera et al., 
1982) and MYCN (which usually is expressed during development and in different immature 
cell types) have been detected across many human neuroblastoma cell lines and tumor 
samples (Kohl et al., 1983; Schwab et al., 1983) and were quickly associated with poor 
patient prognosis (Brodeur et al., 1984; Schwab et al., 1984). In contrast to chromosomal 
translocations of the MYC genes which lead to haematopoietic cancers, activation by 
amplification is often involved in solid human tumors (Meyer and Penn, 2008; Vita and 
Henriksson, 2006). 
There are several other known mechanisms of indirect activation of MYC to date. 
Physiological pathways that activate either MYC or MYCN in normal conditions may 
themselves undergo oncogenic mutations (reviewed in Kress et al. (2015)). Apart from 
activation, enhanced stability of MYC mRNA and protein may also occur as a result of 
deregulation in the various pathways involved (reviewed in Meyer and Penn (2008); (Nilsson 
and Cleveland, 2003). There are also aberrations in other pathways that can prevent removal 
of cells containing activated MYC. One example is p53 or ARF loss of function, which 
disables the cell protective programs like apoptosis, senescence, or cell cycle arrest in the 
event of MYC deregulation, leading to MYC-induced lymphomagenesis (Eischen et al., 
1999). Single-nucleotide polymorphisms (SNPs) affecting proximal promoter elements, distal 
enhancers and super-enhancers that controls MYC transcription also can lead to deregulated 
MYC expression (Dang, 2012; Hydbring et al., 2017). 
Direct mutations in the coding sequence leading to activation, increased stability or reduced 
degradation, are uncommon for MYC, unlike many other oncogenes like RAS. One such 
occurrence in MYC is mutations of the Thr58 and Ser62 residues, leading to stabilized mutant 
proteins. These mutations have been found mostly in Burkitt’s and other lymphomas (Dang, 
2012; Nilsson and Cleveland, 2003). 
Deregulation or activation of MYC alone may not be sufficient to form a tumor as complete 
transformation requires at least two mutations in rodent cells and four to seven mutations in 
human cells (Hahn et al., 1999; Hanahan and Weinberg, 2000; Land et al., 1983; Renan, 
1993). However, MYC overexpression or stabilization, coupled with alterations in the 
apoptotic pathway, results in a pool of cells proliferating uncontrollably with an increased 
risk of acquiring secondary mutations leading to transformation and tumor development (Vita 
and Henriksson, 2006). 
 
Oncogene cooperation  
Studies with MYC not only pioneered the field of oncogene-induced apoptosis. Prior to that, 
experimentations with overexpressed MYC and activated RAS helped established the concept 
of oncogene cooperation (Land et al., 1983). Further work by others increases our 
understanding of the concept better when more cooperating oncogenes partners were found, 
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like MYC and BCL2. The concept of cooperating oncogenes holds true for both human and 
murine systems, albeit with different number of participating aberrations involved (reviewed 
in (Meyer and Penn, 2008)).  
As mentioned in earlier in the MYC and senescence chapter, our group and others had found 
that MYC suppresses activated RAS-induced senescence (Hydbring et al., 2010; Juan et al., 
2014; Tabor et al., 2014). In the same light, RAS has been found to suppress oncogenic 
MYC-induced apoptosis (Kauffmann-Zeh et al., 1997). This explains, at least in part, the 
basis for the MYC/RAS cooperativity that occurs in the rodent system, which is blocking the 
two main anti-tumorigenic mechanisms in the cell. 
One of our thesis projects is to recapitulate the MYC and RAS system in normal human 
fibroblast and examine if these two oncogenes cooperate in the same way in the human cells 
as they do in the rat embryonic fibroblast. The results are discussed later in paper I in the 
Results and Discussions chapter. 
 
1.8.7 Targeting MYC in cancer therapy 
 
The engagement of MYC in many fundamental cellular functions makes it predictable that its 
deregulation has an important role in tumor formation and maintenance. Indeed, MYC has 
been shown to play a role in each of the hallmarks of cancer outlined by Hanahan and 
Weinberg (2011). Within the scope of this thesis, we have only discussed how MYC could 
give rise to cancer through sustained proliferative signaling, resistance of cell death, enabling 
replicative immortality, evasion of growth suppressors and genomic instability and mutation.  
Among the intrinsic tumor suppressor mechanisms triggered by deregulated MYC are 
induction of apoptosis and senescence, and suppression of these programs is vital to 
tumorigenesis. Many experiments have shown that re-enabling the cell suicide pathway can 
force tumor cells to self-destruct (reviewed in Kress et al. (2015); Larsson and Henriksson 
(2010)). 
In mouse tumor models with regulatable MYC expression systems, shut down of MYC often 
leads to rapid and sustained tumor regression, also in tumors driven by RAS, loss of APC etc, 
suggesting that these tumors are “addicted” to MYC (Arvanitis and Felsher, 2006; Jain et al., 
2002). Various tumor models also exhibited regression mediated by apoptosis, senescence 
and/or differentiation upon withdrawal of ectopic MYC expression (reviewed in Dang (2012); 
Kress et al. (2015); Meyer and Penn (2008)). The degenerative phenotypes of normal tissues 
induced by systemic MYC inhibition were rapidly and completely reversible on restoration of 
MYC function, and were shown to be tolerable for the animals (Sodir et al., 2011; Soucek et 
al., 2008). These observations suggest that inhibition of MYC is a possible way of eradicating 
not only MYC-driven tumors, but also those initiated by other oncogenes, making MYC a 
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tempting target for therapy (Alderton, 2011; Castell and Larsson, 2015; Larsson and 
Henriksson, 2010; Prochownik and Vogt, 2010; Vita and Henriksson, 2006). 
Insights into MYC biology and cofactor-interactions have been useful to strategize different 
ways of therapeutically targeting MYC and developing new MYC inhibitors. However, no 
specific anti-MYC drugs are clinically available today (Castell et al., 2018).  
Pharmacological targeting of MYC has proven to be challenging. Several groups have 
attempted to target MYC indirectly through targeting the different pathways regulating MYC 
at different levels, including transcription, translation or stability of the mRNA or proteins, 
but many have limited success due to the multiple ways whereby the tumors can escape 
(Castell and Larsson, 2015; McKeown and Bradner, 2014; Whitfield et al., 2017). One 
strategy that has gained interest recently is the targeting of the bromo and extra terminal 
(BET) domain-containing transcription regulator BRD4, which is important in transcription 
of MYC gene in many cells. BRD4 binds acetylated lysines in histones on the chromatin and 
contributes to the transcription process. A small molecule inhibitor, JQ1, was found to 
interfere this interaction by binding to the domain of BRD4 important for this interaction 
(Fletcher and Prochownik, 2014; McKeown and Bradner, 2014). Pre-clinical models, 
including of hematopoietic cancers and neuroblastoma, indicated that JQ1 is able to inhibit 
tumorigenesis. However, it is found to work only in some tumor types but not others 
(Alderton, 2011; Delmore et al., 2011; Loven et al., 2013; Mertz et al., 2011; Puissant et al., 
2013). 
Another way of devising strategies is to target MYC directly, but that turns out to be not very 
straightforward, due to it lacking enzymatic active sites (Prochownik and Vogt, 2010) and 
being an intrinsically disordered protein (IDP) (Dyson and Wright, 2005).   
Studies into targeting protein-protein interactions (PPIs) of IDP proteins, including of MYC, 
have given insight that it is possible to target limited binding surfaces (Fletcher and 
Prochownik, 2015; Follis et al., 2008; Hammoudeh et al., 2009; Michel and Cuchillo, 2012; 
Prochownik and Vogt, 2010). Since heterodimerization with MAX is crucial for MYC to 
bind to E-boxes for its transcriptional and oncogenic activity (Meyer and Penn, 2008), it is a 
conceivable approach to target MYC:MAX interaction. 
Small molecules inhibitors used successfully to inhibit PPIs (Filippakopoulos et al., 2010; 
Fletcher and Prochownik, 2014; Lane et al., 2010; Saha et al., 2013; Tse et al., 2008; Vassilev 
et al., 2004) and leading to clinical trials (Arkin et al., 2014; Nero et al., 2014), have spurred 
interest of MYC researchers to dive into the search for small molecule inhibitors of 
MYC:MAX interaction. Screening of small-molecule libraries have led to the identification 
of several compounds by different groups. Unfortunately, these compounds have a number of 
limitations including relatively low potency in vitro or in cells, poor specificity or insufficient 
bioavailability in vivo, and thus have not made their way for clinical studies (Fletcher and 
Prochownik, 2015; McKeown and Bradner, 2014; Prochownik and Vogt, 2010; Whitfield et 
al., 2017).  
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In our work, we have identified a compound MYCMI-6 that is able to bind MYC directly 
with high affinity, and inhibit the MYC:MAX interaction efficiently and selectively in vitro 
and in cells. Moreover, this compound is active in vivo and inhibits MYC-dependent tumor 
cell growth with high efficacy without affecting MYC expression (Castell et al., 2018). The 
work will be discussed in more detail in the result and discussion section (paper IV).  
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2 AIMS OF THIS THESIS 
 
Interaction and cooperation between MYC and different cofactors/ proteins are absolutely 
essential for the different functions of MYC and its stability. The overall aim of this thesis is 
to deepen our understanding of several different proteins that cooperate and interact with 
MYC (Paper I to III), and identify small molecules that would target specific interactions 
involving MYC (Paper IV). The outcome is hopefully to identify possible strategies to 
suppress the tumorigenic function of MYC or, alternatively, enhance its anti-tumorigenic 
function, such as induction of apoptosis and senescence, as a way of counteracting MYC in 
cancer cells driven by MYC or other cooperating oncogenes, particularly, RAS. 
 
More specifically, the aims are: 
I. To investigate the oncogenic cooperativity between MYC and RAS in normal human 
fibroblasts with regards to senescence and apoptosis regulation  
 
II. To elucidate the mechanism by which IFN-ɣ inhibits MYC function, in particular via 
p27, and the involvement of ubiquitin-proteosome system 
 
III. Identify novel F-box proteins that has implications in cancer, and characterize the role 
of the novel SCFFBXO28 E3 ubiquitin ligase complex in regulating MYC’s function 
 
IV. To identify and validate small molecules inhibitors of MYC:MAX interaction and to 
evaluate their biological activity and selectivity towards MYC-driven tumor cells vs. 
normal cells  
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3 RESULTS AND DISCUSSIONS 
 
3.1 PAPER I 
 
MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis 
in normal human fibroblasts 
 
For several decades, co-expression of MYC and RAS had been known to be sufficient to 
transform cells in rodent based models (Hydbring et al., 2010; Land et al., 1983; Larsson and 
Henriksson, 2010; Meyer and Penn, 2008; Pulverer et al., 1994). The mechanism can be 
partly explained by the capability of RAS to override MYC-induced apoptosis (Kauffmann-
Zeh et al., 1997) and MYC to override RAS-induced senescence (Hydbring et al., 2010). In 
this study, we sought to understand if MYC and RAS cooperate to suppress these fail-safe 
mechanisms in human cells in a similar way as in rodent cells.  
We first aimed to create a stable dual inducible system, so as to avoid transfection 
inefficiencies and instabilities. Such a system would also allow us to easily control the 
expression of the vectors and remove the stress of transient transfection in each setting.  To 
this end, we used normal human BJ fibroblasts that were stably transduced with tetracycline-
regulated H-RASV12 as previously described in Evangelou et al. (2013) and Maya-Mendoza 
et al. (2015), and stably introduced 4-hydroxytamoxifen (OHT)-controlled MycER 
expression/activation system. In this system, MYC activation alone led to apoptosis, whereas 
RAS activation alone led to premature cellular senescence, in line with well-known reports of 
the intrinsic fail-safe programs elicited by these two oncogenes (Evan et al., 1992; Serrano et 
al., 1997). These were accompanied by DNA damage and upregulation of p53 (Figure 4A).  
When the two oncogenes were activated concurrently, the cells undergo apoptosis, DNA 
damage (ɣH2AX) and p53 induction, similar to the cell culture with MYC activation alone. 
The cells that did not undergo apoptosis seemed to be pushed into senescence like the cells 
activated by RAS alone, as shown by β-Gal staining and induction of p16INK4A. However, 
there is a reduced staining in one senescence marker, the histone H3 lysine 9 trimethylation 
(H3K9me3) in these dual-induced cells compared to RAS induction alone (Figure 4, all 
panels). H3K9me3 is associated with cellular senescence in some cells, including BJs, 
depending on the stimulus, and often follow the expression of p16 (Kosar et al., 2011).  
Since p53 plays an important role in oncogene-induced apoptosis and senescence, and we 
observed induction of p53 upon MYC activation, we then stably knocked down p53 using 
short hairpin RNA (shRNA). We found that p53 depletion only rescued cells from 
senescence, both induced by RAS and MYC, but not MYC-induced apoptosis whether with 
or without RAS co-activation. Additionally, the triple insult caused the cell culture to undergo 
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apoptosis after a few days (Figure 5, all panels). Hence, our study shows that MYC and RAS 
do not cooperate to bypass senescence and apoptosis in human BJ cells, even when p53 is 
removed. Additional mutational events must occur, not just for the transformation of normal 
human fibroblasts (Vogelstein and Kinzler, 1993), also for suppression of senescence and 
apoptosis. Unlike the rodent model, coexpression of MYC and RAS in the human BJ model 
is insufficient for the cross suppression of these two anti-tumorigenic processes. 
One possible explanation for the lack of cooperation between these two oncogenes is that 
MYC enhanced, instead of suppressed p16 expression in RAS-induced BJ cells (Figure 4A). 
p16 is known to maintain pRB activity, and thus can lead to reinforcement of the RAS-
induced senescence in fibroblasts. Previous reports had shown that rodent and human cells 
with reduced or loss of p16 expression can overcome RAS-induced senescence (Drayton et 
al., 2003; Huot et al., 2002; Lin et al., 1998; Serrano et al., 1997). 
In contrast to our results, previous studies using human normal melanocytes had shown that 
MYC is able to overcome either BRAF- or NRAS-induced senescence (Zhuang et al., 2008). 
Further, melanomas with activated BRAF/NRAS undergo senescence upon MYC 
knockdown, in a p16- and p53-independent manner. This shows that senescence is regulated 
differently in different cell types. 
We conclude that MYC and RAS do not cooperate by cancelling out each other’s fail safe 
mechanisms in normal human fibroblasts as they do in the rodent fibroblasts, even with the 
removal of the tumor suppressor p53. This indicates that tumorigenesis in human cells takes a 
different route and require other or additional mutations to activate oncogenic pathways 
and/or deactivate tumor suppressor pathways (including senescence and apoptosis) that lead 
to cell transformation and development of cancer. Further, other reports showing that these 
two oncogenes cooperate in normal human melanocytes indicate that senescence regulation 
in different human cell types may work differently. This finding also impact the way we 
study animal models and translate the outcomes into the human system, in this case with 
regards to the transformation process in human cells and extrapolating results into future 
clinical studies. 
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3.2 PAPER II 
 
Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated 
degradation 
 
Earlier, our group had shown that CDK2-mediated phosphorylation of MYC at Ser-62 is 
important for MYC’s role in suppressing two barriers of transformation: senescence and 
differentiation. Further, pharmacological and physiological inhibition of CDK2 by CVT313 
or p27 respectively, restored senescence and differentiation (Campaner et al., 2010; Hydbring 
et al., 2010). 
In this paper, we show that p27, via mechanisms independent of CDK2, can also induce 
senescence and degrade MYC through the ubiquitin-proteosome system via its C-terminus.  
Additionally, there is a significant correlation between high expression of active p27 protein 
with low MYC protein level in human breast cancer, with implications in prognosis. 
Firstly, we demonstrated here that p27 is able to override MYC’s suppression of activated 
RAS-induced senescence regardless of MYC Ser-62 status. We then showed that p27 affects 
MYC protein expression levels by inducing degradation of the MYC protein via the 
ubiquitin-proteosome system. 
Expression of p27 protein can be stimulated by grown inhibitory cytokines, such as IFN-ɣ 
and TGF-β. Here, we showed that IFN-ɣ treatment leads to increased degradation of MYC in 
several cell lines; U-937 cells, Colo-320 colon carcinoma cells with amplified MYC and 
human 2fTGH fibrosarcoma cells. This is accompanied by increased MYC ubiquitylation and 
upregulation of p27. A p27 null cell line, p27-/- mouse embryonic fibroblast (MEF), does not 
have reduced MYC protein level upon IFN-ɣ treatment, even though the wildtype MEFs 
does. Thus, IFN-ɣ induces degradation of MYC via the ubiquitin-proteosome system, 
mediated by p27. By using fluorescent reporter protein and BiFC, we localized the IFN-ɣ-
induced degradation of MYC to the nucleus, predominantly in the nucleoli, as previously 
suggested as the site of rapid MYC turnover (Arabi et al., 2005), and in complex with Max. 
The mechanism is dependent on the Jak/Stat pathway but is independent of MYC Thr-58 
phosphorylation site, which is pivotal in MYC’s degradation via Fbxw7. Using dominant-
negative SKP2ΔF mutant, we also showed that SKP2 is not involved in p27-mediated 
degradation of MYC. Hence a new unknown E3 ligase is implicated in p27 degradation of 
MYC. 
We further addressed the mechanism through which p27 promotes degradation of MYC. We 
found that p27 interacts directly with MYC in the nucleus. After mapping the domains, we 
found that MYC binding to p27 requires amino acids 294 – 366 of MYC, which contains the 
MYC Box 4 (MB4), the nuclear localization signal (NLS) and the basic DNA binding region 
of MYC. Binding of p27 to MYC requires the C-terminal part of p27 (amino acids 82 – 198), 
 36 
which contains several regulatory phosphorylation sites such as T187, T157 and T198, and 
the part important for p27 nuclear export. The p27 C-terminus is sufficient to induce MYC 
degradation without involving CDK2 nor affecting MYC mRNA levels. 
We investigated further the correlation between p27 and MYC in human tumors, to tumor 
grade and patient outcome. Selecting the breast invasive carcinoma (BRCA) data set from 
The Cancer Genome Atlas (TCGA) (2012) data portal (Zhu et al., 2009) for sufficient 
statistical power, we found no significant correlation between MYC and p27 expression 
levels as a whole. However, a subpopulation with high p27 expression but low level of 
phosphorylation of p27 at the T157 Akt/Rsk/Pim1 phosphorylation site, which is the 
signature of cytoplasmic p27 that will not affect CDK2 or the nuclear functions of MYC, has 
a strong inverse correlation with MYC protein levels. Correlating this selected group to 
clinical parameters showed a positive correlation with good prognostic markers, namely 
grade 1 tumors, luminal A subtype, estrogen receptor (ER) positivity and Her2 negativity, 
and a negative correlation with poor prognostic markers, namely grade III and IV tumors, 
basal and Her2 subtypes, ER negativity and Her2 positivity. A second subpopulation with 
high p27 and low MYC protein levels, and low phosphorylation of the retinoblastoma protein 
protein (pRb) at CDK-sites (a functional readout of p27 activity) correlated significantly with 
relapse-free patient survival and overall patient survival. 
Taken together, in this paper, we showed that IFN-ɣ-induced p27 induces senescence and 
degrades MYC independently of CDK2 and MYC Thr-58 phosphorylation. This occurred 
through the ubiquitin-proteosome system via an unknown E3 ligase. Additionally, there is a 
significant correlation between high expression of active nuclear p27 protein with low MYC 
protein level in human breast cancer, and this correlates positively with favourable prognostic 
markers, relapse-free patient survival and overall patient survival. These results may support 
immunotherapeutic approaches of targeting MYC-driven tumors in future. 
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3.3 PAPER III 
 
CDK-mediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC-driven 
transcription and tumorigenesis and predicts poor survival in breast cancer 
 
This project was aimed at identifying F-box genes involved in cell proliferation that may 
have a role in tumor growth. Two screens were employed, the first using an siRNA library 
targeting all human F-box genes and the second was on the whole genome, which included 
53 F-box genes. In both screens, FBXO28, a novel uncharacterized F-box protein, is among 
the top candidate that, upon knock-down, led to a highly significant reduction in cell 
proliferation in several tumor-derived cell lines.  
Microarray expression analyses showed that FBXO28 depletion resulted in significant 
downregulation of genes involved in important biological processes including rRNA 
processing, ribosome biogenesis, cell cycle and metabolism. These set of processes are 
reminiscent of those regulated by MYC. Further Gene Set Enrichment Analysis (GSEA) 
confirmed that MYC target genes were downregulated upon FBXO28 depletion and this was 
confirmed by qRTPCR. When FBXO28 and MYC were both knocked down at the same 
time, the proliferation rate was similar to the single knock down of FBXO28. This indicated 
that MYC and FBXO28 are possibly involved in similar pathways, and hence we proceeded 
to characterize FBXO28 and elucidate the relationship between FBXO28 and MYC. 
Mass spectrometric analysis of purified FBXO28 showed serine 344 (S344) to be a specific 
phosphorylation site of the protein. Phosphorylation stabilized the protein and localized it to 
the nucleus. We also found that cyclin A‐CDK2 and cyclin B‐CDK1 phosphorylate this site, 
but not cyclin E‐CDK2, and that phosphorylation of FBXO28 was at the maximum at S-
G2/M phase and minimum at early G1 phase.  
We discovered that FBXO28 forms a SCFFBXO28 ubiquitin ligase with SKP1 and CUL1, 
independently of phosphorylation status. Phosphorylation of the protein at serine 344 enables 
the ubiquitin ligase complex to target MYC for ubiquitylation. Further, we also showed that 
the phospho-mimetic form of FBXO28, S344E-FBXO28, is able to ubiquitylate MYC, but 
not the phospho-deficient S344A-FBXO28. However, cycloheximide chase experiments 
indicated that MYC was not degraded upon ubiquitylation by FBXO28. 
Interaction mapping analysis indicated that FBXO28 binds MYC at the MYC Box II (MBII) 
and possibly the helix-loop-helix leucine zipper (HLH-LZ) domain of MYC. By using in situ 
Proximity Ligation Assay (isPLA), we also showed that FBXO28 co-localizes with MYC 
endogenously in the nucleus, and by chromatin immunoprecipitation assays (ChIP), we 
showed that it binds with MYC in the E‐box region. Thus FBXO28 interacts with and binds 
MYC at the promoters. We also found that upon ubiquitylation by SCFFBXO28 the cofactor 
p300 was recruited to MYC target gene promoters.  
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Knock down of FBXO28 was found to attenuate MYC ubiquitylation. We also found that an 
F‐box deletion mutant, ΔF‐FBXO28, can bind MYC, but as it cannot form the SCF complex, 
ΔF‐FBXO28 failed to ubiquitylate MYC. This suggests that ΔF‐FBXO28 acts in a dominant 
negative way. Interestingly, ΔF‐FBXO28 overexpression also reduced the interaction of p300 
and histone H4 acetylation at MYC target gene promoters, though MYC-MAX binding was 
not significantly affected. Unsurprisingly, overexpression of ΔF‐FBXO28 or FBXO28 knock 
down led to reduced MYC-dependent luciferase reporter gene activity. Taken together, this 
indicated that FBXO28 binds and ubiquitylates MYC in a non-proteolytic manner and 
regulate MYC transcriptional activity of genes important in proliferation.  
We further investigated the role of FBXO28 in tumorigenesis. Interestingly, expression of 
ΔF‐FBXO28 or FBXO28 knock down led to reduction in both colony growth in 2D cultures, 
and MYC-induced transformation in a 3D soft agar assay and tumor growth in vivo in an 
immunodeficient mouse tumor model system. When expressing mutant FBXO28 that is 
incapable of being phosphorylated by CDK1/2 (S344A‐FBXO28), the growth of tumor cells 
slowed down and the ability of MYC to transform p53‐/‐ MEFs was strikingly reduced. This 
suggests that FBXO28 activates MYC in a CDK1/2-dependant manner, possibly in the cell 
cycle. 
Next, we searched through the GeneSapiens System transcriptomics database (www. 
genesapiens.org) and the Oncomine database, and found that FBXO28 is highly expressed in 
various tumor types, such as breast cancer. We further investigated FBXO28 expression in 
gene expression data of 327 primary breast tumor specimens, and found correlation between 
expression of FBXO28 with more than 100 genes, most of which are positive correlation 
when analyzed through ENCODE (http://genome.ucsc.edu/ENCODE/ analyses). There is 
also a significantly high representation of MYC and p300 association at the promoters. 
In order to establish a possible clinical significance of FBXO28 in human breast cancer, we 
analyzed a panel of 144 primary breast cancers for FBXO28 phosphorylation using 
immunohistochemistry on tissue microarray (TMA). We found that most of the tumors 
showed high nuclear intensity, though there was a significant difference in the nuclear 
fraction (NF) of pS344‐FBXO28 between the different tumors. Interestingly, we found a 
correlation between a high NF of pS344‐FBXO28 in samples with other markers of poor 
patient outcome, such as tumor size, high grade and estrogen receptor (ER) ‐negative status. 
Multivariate analysis also indicated that FBXO28 expression and phosphorylation could 
independently predict poor survival. 
In summary, we have identified a novel F-box protein, FBXO28, which is a substrate of 
CDK1/2 and tightly regulated during cell cycle progression. FBXO28 assembles an 
SCFFBXO28 ubiquitin ligase and, upon phosphorylation, ubiquitylates MYC, thereby enabling 
MYC to recruit p300 to promoters of MYC target genes and activate MYC transcription of 
genes important for proliferation. Silencing or aberrant expression of FBXO28 leads to 
attenuation of MYC-driven transcription, proliferation, transformation and tumor growth. We 
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also found that phosphorylated FBXO28 is an independent prognostic marker of poor overall 
survival in breast cancer patients. Hence, the CDK-FBXO28-MYC axis may be a potential 
target for drug discovery for MYC-driven cancers, particularly breast cancer. 
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3.4 PAPER IV 
 
A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and 
MYC-dependent tumor cell proliferation 
 
MYC is involved in many important cell processes and is a key player in tumorigenesis. 
However, to date, no specific anti-MYC drugs have reached clinical development. Previous 
efforts targeting other drivers like EGFR and BRAF have led to resistance via activation of 
redundant pathways, which all activate MYC. It is therefore important to target MYC. The 
best strategy would be to target MYC directly since there is a risk of escape with indirect 
targeting (Castell and Larsson, 2015; McKeown and Bradner, 2014; Whitfield et al., 2017). 
One Achilles’ heel of MYC is its dependency on interacting with MAX protein for its 
transcriptional function, and hence tumorigenesis (Meyer and Penn, 2008). Thus, targeting 
this interaction is a plausible way of crippling MYC function. Attempts by others to target 
other protein-protein interactions had proven to be fruitful and are now in clinical trials but 
yet, there had been limited success in targeting MYC:MAX interaction, namely due to low 
potency, specificity or bioavailability (Fletcher and Prochownik, 2015; McKeown and 
Bradner, 2014; Prochownik and Vogt, 2010; Whitfield et al., 2017). 
In this project, we used a cell-based Bimolecular Fluorescence Complementation (BiFC) 
assay (Kerppola, 2006) in a protein interaction screen that is specifically designed to identify 
small molecules that inhibit MYC:MAX interaction. The main advantage of this assay is its 
use of life cells, and hence it already screens out small molecules that are not able to enter 
cells or that are generally cytotoxic. From a diversity set library of NCI/DTP Open Chemical 
Repository (http://dtp.cancer.gov), we screened 1990 compounds at 25µM concentration and 
identified six molecules for further investigation that we termed MYCMIs (MYC:MAX 
Inhibitors): MYCMI 2, 6, 7, 9, 11 and 14. These compounds reduced the BiFC/CFP readout 
by more than 40%, normalized to DMSO (vehicle), the most potent being MYCMI 6 and 7, 
and do not affect the control pair of bZip transcription factors, namely FOS and JUN. 
These hits were then validated using other techniques. Split Gaussia luciferase (GLuc) assay 
(Remy and Michnick, 2006) is a high/mid-throughput method used to validate that the 
inhibitory effects are on MYC:MAX, and not the fluorescence molecule in BiFC itself or 
other bZip transcription factors (GCN4 homodimer was used for this control). By western 
blot analysis, we also sieved out compounds that reduced MYC protein expression (MYCMI 
7 and 9), as that was not the mechanism of action we were looking for in this case. Our aim is 
to identify compounds that only inhibit the interaction between MYC and MAX, without 
affecting MYC protein levels or other MYC activities. This is due to the experience of others 
who attempted to target MYC indirectly via different pathways that regulate MYC, but have 
met with limited success as there are multiple escape routes for the tumors through other 
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redundant pathways (Castell and Larsson, 2015; McKeown and Bradner, 2014; Whitfield et 
al., 2017). Thus, from this point, we focused on three hits, MYCMI 6, 11 and 14.  
We next applied in situ proximity ligation assay (isPLA) to confirm that the selected 
compounds inhibits endogenous MYC:MAX interactions in cells (Soderberg et al., 2006). 
The readout is nuclear fluorescent dots, and is evaluated by fluorescence microscopy. We 
also performed a titration and found that compound MYCMI-6 has an IC50 of less than 1.5 
µM and MYCMI 11 and 14 has IC50 of about 6 µM for MYC:MAX inhibition. Furthermore, 
MYCMI-6 affected endogenous MYC:MAX interaction already 3 hours after the treatment, 
as shown by coimmunoprecipitation. All the three compounds shows the selectivity for 
MYC:MAX interaction as they do not affect other bZip protein partners FRA1:JUN and 
MAX:MXD1(MAD1). Investigation on the effect of these compounds on transcription of 
MYC target genes ODC1, RSG16 and CR2 revealed that MYCMI-6 reduced the expression 
of all these genes significantly, while MYCMI 11 and 14 only significantly reduced RSG16 
expression. Taken together, these results revealed MYCMI-6 to be the most selective and 
potent inhibitor of MYC:MAX interactions and MYC-driven transcription in vivo. 
Further, we evaluated MYCMI-6 in in vitro assays based on recombinant MYC and MAX 
proteins, microscale thermophosis (MST) and surface plasmon resonance (SPR) (manuscript 
in prep.). In MST assay, a shift in the reading compared to DMSO indicates an effect on the 
conformation of the protein pair. We found MYCMI-6 to cause a thermophoresis shift with a 
Kd of 4.3 +/– 2.9 µM in a mixture with MYC and labeled MAX, but causing minimal change 
in a labeled MAX:MAX mixture. This indicates that MYCMI-6 differentially inhibits 
MYC:MAX interactions.  
SPR analysis can determine the affinity between protein and ligand, and measure the 
interaction kinetics with high sensitivity. In this analysis, MAXbHLHZip that was covalently 
bound to the sensor chip, and MYCMI-6 premixed with MYCbHLHZip was added. 
MYCMI-6 inhibited MYCbHLHZip from binding to MAXbHLHZip with an IC50 of 3.8 +/– 
1.2 µM, which is more efficient than that of other experimental MYC inhibitors 10058-F4 
(Yin et al., 2003) and KJ-Pyr-9 (Hart et al., 2014) we tested here. Further investigations 
indicated that MYCMI-6 binds the bHLHZip domain of Myc directly, and more efficiently 
than other MYC:MAX inhibitors 10074-G5, #474 (10058-F4 analouge) (Wang et al., 2007c) 
and KJ-Pyr-9. MYCMI-6 binding to MAX, MXD1 (MAD1), p53, BSA, YFP or BCL-XL is 
negligible or minimal. All these results point to MYCMI-6 being a direct, selective and 
potent inhibitor of MYC protein. 
Next, we tested if MYCMI 6 (6.25 µM), 11 (25 µM) and 14 (25 µM), with 10058-F4 (64 
µM) as reference, would inhibit MYCN-driven tumor growth in neuroblastoma cell lines with 
or without MYCN-amplification. The growth of MYCN-amplified cell lines were more 
significantly reduced than that of the MYCN-non-amplified cell lines by all four compounds. 
Titration of MYCMI-6 gives an average growth inhibition (GI50) values of 2.5-6 µM for the 
former and 20 µM or higher for the latter group of cell lines. In a cell line where MYCN or 
MYC was hardly detectable (SK-N-F1), there was essentially no response with MYCMI-6. 
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Further, anchorage-independent growth of MYCN-amplified neuroblastoma cell lines were 
inhibited by MYCMI 6, 11 and 14 with GI50 values of less than 0.4, 5 and 0.75 µM, 
respectively. Altogether, these results showed that MYCMI-6 is more potent and selective 
among the MYCMIs and is selected to be the focus of the rest of our study. 
Taking into account the MYC mRNA/protein levels of different cell lines, we analyzed 
available data on the growth inhibitory effects of MYCMI-6 from the NCI-60 diverse human 
tumor cell line panel. We found that MYCMI-6 has a significantly higher growth inhibitory 
effect in human cancer cell lines that have higher MYC mRNA/protein expression, although 
there was no significance based on MYC mRNA data alone. We tested the MYC dependence 
further using Tgr1 rat fibroblast (parental cells), and its MYC-null (H015.19) and MYC-
reconstituted variants (H0Myc3), and found that, similarly, MYCMI-6 treatment has a MYC-
dependent effect. In addition, comparison between the effects of MYCMI-6 on MYCN-
amplified SK-N-DZ neuroblastoma and normal lung (IMR-90) and foreskin (BJ) human 
fibroblasts showed that the compound can be well tolerated by normal human cells at the 
same concentration (12.5 µM) that was highly toxic to a tumor cell with high MYC. Thus, 
this indicates that MYCMI-6 functions in a MYC-dependent manner and has a good 
therapeutic window.  
To evaluate the tumor physiopathology effects of MYCMI-6 in vivo, we used a mouse 
xenograft tumor model where we injected MYCN-amplified SK-N-DZ neuroblastoma cells 
into the flanks of athymic nude mice, and after tumor formation MYCMI-6 or vehicle were 
administered. 1-2 weeks later the mice were sacrificed and evaluated for several parameters. 
We found that there is reduction in MYCN:MAX interaction (by isPLA), tumor cell 
proliferation (by Ki67 staining) and microvascular density (MVD) (by CD31 staining of 
endothelial cells) in MYCMI-6-treated mouse compared to vehicle treatment. On the other 
hand, there is increase in apoptosis (by TUNEL staining), signs of necrosis, hemorrhage and 
scar tissue formation in the compound-treated cells, with only a slight and temporary effect 
on body weight, indicating that the side effects are well-tolerable.  
Taken together, we have found a small molecule, MYCMI-6 that inhibits 
MYC/MYCN:MAX interactions in human and rat cells, in vitro and in vivo (in mouse tumor 
model), and reduced tumor growth or kill tumor cells in a MYC-dependent manner, without 
severe side effects.   
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4 SUMMARY AND CONCLUSIONS 
 
MYC is a master regulator of transcription but its function and regulation is dependent on 
interaction with other proteins and it also works in cooperation with other oncogenes. 
Overexpression of MYC alone leads to apoptosis but not to tumor development. Nonetheless, 
deregulated expression of MYC plays an important role in tumorigenesis. It has even been 
suggested that a low level of MYC expression contributes more to tumorigenesis since a 
higher level of overexpression engages the apoptotic pathway (Murphy et al., 2008). 
However, by cooperating with other oncogenes like RAS, accompanied by deregulation of 
tumor suppressor pathways, high levels of MYC can be tolerated and leads to aggressive 
tumor progression. MYC-driven tumors are often strongly correlated with poor prognosis.  
Inactivation of MYC had been shown to lead to tumor regression with well-tolerated side 
effects (Soucek et al., 2008), often accompanied by senescence (Wu et al., 2007) or apoptosis 
(Soucek et al., 2008). This suggests that MYC is a potential and suitable target for anti-cancer 
therapy. MYC itself is very difficult to target as it is unstructured and does not have an 
enzymatic activity. MYC:MAX interaction is known to be important for the DNA binding 
function of MYC, however, targeting this protein-protein interaction is a challenge because of 
the lack of any enzymatic active site and the intrinsic disordered nature of the proteins. The 
purpose of this thesis was to elucidate the pathway of interaction between overexpressed 
MYC and activated RAS in normal human fibroblasts, and determine if they interact the 
same way in these cell as in their rodent counterpart. We also wanted to identify new MYC 
cofactors and dissect the mechanism by which they interact and may contribute to 
tumorigenesis. Finally, our aim was to also find new strategies to target MYC by identifying 
potent and selective inhibitors of the MYC:MAX interaction.  
In Paper I, we showed that oncogenic MYC and RAS do not cooperate in normal human 
fibroblasts as they do in rat embryonic fibroblasts, to cancel out each other’s intrinsic anti-
tumorigenic barrier, namely apoptosis and senescence, even in the absence of tumor 
suppressor p53. Hence, additional mutations are required for the development of MYC- and 
RAS-driven tumors in human, and to override the intrinsic tumor suppressor pathways of 
these oncogenes. This sheds light on how oncogenic transformation proceeds in human cells.  
In Paper II, we discovered a new pathway and interactors that regulate MYC turnover. We 
found that p27 targets Myc both indirectly through CDK2 and directly by binding MYC, 
resulting in MYC degradation, removal of MYC binding to target gene promoters. This 
resulted in lowered expression of MYC target genes, and senescence and differentiation of 
MYC-driven tumor cells. Since p27 can be stimulated by growth inhibitory cytokines, such 
as IFN-ɣ, we also investigated if IFN-ɣ treatment leads to the degradation of MYC, and it 
does, via the upregulation of p27. Interestingly, we found that this degradation process occurs 
via an E3 ligase that is not currently known in the MYC regulation repertoire. It would be of 
future scientific interest to identify this E3 ligase. We have also found that there is significant 
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clinical relevance between high activity of nuclear p27 levels and low MYC expression in 
tumor samples, and this correlates with a good prognosis and a positive clinical outcome. 
Thus a new strategy to target MYC-driven tumors is by finding ways to upregulate p27 
expression and activity. One of the possible ways is by utilizing IFN-ɣ, which is one of the 
cytokines produced by activated T-lymphocytes. This may provide support to develop 
immunotherapy methods to combat MYC-driven tumors, in particular enhancing IFN-ɣ-
producing T-cells, as a complementary treatment along with molecular therapies targeting 
CDK2 or signaling pathways that enhances p27 expression/activity. 
In Paper III, we uncovered a novel F-box protein, FBXO28, that ubiquitylates MYC in a non-
proteolytic manner, and enhances MYC transcriptional activity and downstream pathways. 
SCFFBXO28 is phosphorylated by CDK1/2 during the cell cycle, which regulates its activity 
and stability, and is required for its efficient ubiquitylation of MYC. When FBXO28 is 
depleted or a dominant negative F-box mutant is overexpressed, it cannot support MYC 
ubiquitylation, and results in reduction of MYC-driven transcription, transformation and 
tumorigenesis. We also found that high MYC expression coupled with high FBXO28 
expression and phosphorylation are strong and independent predictors of poor prognosis in 
human breast cancer. In conclusion, our data suggest that the CDK-FBXO28-MYC axis is a 
potential molecular drug target in MYC-driven cancers, including breast cancer. 
In Paper IV, despite the difficulty in targeting protein-protein interactions, especially that of 
unstructured proteins such as MYC, we found a small molecule that binds MYC and inhibits 
MYC:MAX interaction. We found MYCMI-6 to inhibit MYC/MYCN:MAX interactions in 
human and rat cells, in vitro and in vivo (in mouse tumor model). Further, this compound 
impeded tumor growth and killed tumor cells in a MYC-dependent manner, both in cells and 
in vivo. Importantly, this is achieved with specificity to tumor cells expressing high levels of 
MYC, high potency (low concentration needed), a good therapeutic window and without 
severe side effects. Apart from being a prototype and proof of principle of protein-protein 
targeting, we discovered MYCMI-6 as a unique molecular tool to target MYC:MAX 
pharmacologically with high specificity and efficacy, and it is a good candidate for drug 
development.      
Altogether, the projects involved in this thesis provide insights into molecular pathways 
involved in MYC oncogenic activity, regulation, and transcription functions. We identified a 
difference in pathways of cooperation between oncogenic MYC and RAS in rats and human 
(Paper I), found new cooperating protein partners and possible therapeutic targets (Paper II 
and III), and provided proof of principle/ concept of targeting non-enzymatic protein-protein 
interaction (Paper IV). This will be of importance not only to increase the basic knowledge 
on mechanisms through which MYC contributes to tumor development, but will hopefully 
also contribute to the development of new therapeutic strategies to combat MYC-driven 
cancer in the future. 
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